Anticancer drugs targeting angiogenesis act either directly on vascular endothelial growth factor (VEGF) receptors (VEGF inhibitors) or VEGF-mediated intracellular processes (tyrosine kinase inhibitors) or indirectly through downstream VEGF signaling within broader processes (mammalian target of rapamycin inhibitors and multiprotein kinase inhibitors). Although VEGF blockade may be implicated in arterial wall injuries, the literature on the association between antiangiogenic drugs and artery dissections or aneurysms is scant, comprising only a few case reports and 1 pharmacovigilance study conducted in Japan.1 The present study evaluated the association between all antiangiogenic drugs and dissections or aneurysms occurring in all arteries.< Réduire

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche